Authors
Latest:
Redefining the Role of Pathology in the Molecular Era: Away From the Microscope? Not So FastAndre Goy, MD, discusses how pathologists will continue to play a critical role in oncology care, even with the technological advances of the molecular era.
Latest:
Genomic Sequencing and Identifying Driver Mutations in AML and MDSIlaria Iacobucci, PhD, discusses integrated transcriptomic and genomic sequencing to identify prognostic constellations of driver mutations in AML and MDS.
Latest:
Racial/Ethnic and Age Disparities in Chemotherapy Selection for Colorectal CancerStudies have evaluated racial/ethnic and age disparities in whether patients receive chemotherapy for nonmetastatic colo-rectal cancer
Latest:
Dr. Tabbara on Treatment for Transplant-Eligible and -Ineligible Patients With Multiple MyelomaImad Tabbara, MD, discusses available treatment options for transplant-eligible and -ineligible patients with multiple myeloma.
Latest:
Do No HarmIt is hard as a physician not to feel the sting of failure when you lose a patient. Yet, it serves as a reminder that at the end of the day, we uphold our oath by knowing when enough is enough, by ensuring that there is dignity, not only during life, but also in death.
Latest:
Conditions Are Better for Women in Oncology But More Work Needs to Be DoneDespite the strides made by women over the past 170 years, significant disparities remain, especially in academic medicine.
Latest:
Dr. Lennes Discusses Ongoing Research on Screening Techniques for Lung CancerInga T. Lennes, MD, MBA, MPH, senior vice president of Performance Improvement and Service Excellence of the Mass General Physicians Organization, medical director, Ambulatory Services, and director of clinical quality, Massachusetts General Hospital Cancer Center, discusses ongoing research on screening techniques for lung cancer.
Latest:
Dr. Haldorsen on Overcoming Challenges With Imaging in Endometrial CancerIngfrid Haldorsen, MD, University of Bergen, Haukeland University Hospital, on overcoming challenges with imaging in endometrial cancer.
Latest:
Dr. Ingrid Mayer on Targeted Therapies in ER+ Breast CancerIngrid A. Mayer, MD, co-leader and Clinical Director, Breast Cancer Research Program Chair, Data and Safety Monitoring Committee, Associate Professor of Medicine (Hematology/Oncology), medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the use of targeted therapies in estrogen-receptor (ER)-positive breast cancer.
Latest:
Development of PI3K Inhibitors in Breast CancerThe PI3K pathway is the most frequently altered pathway in cancer, and its activation has been shown to confer resistance to endocrine and HER2-targeted therapies preclinically.
Latest:
Oncology Enters the Informatics Era: Many Eager to Jump on the Health Information HighwayThe unifying principle for care delivery in every situation should ideally be centered on complete clinical information, coupled with evidence-based medicine, and filtered through clinical decision support tools.
Latest:
Dr. Winer on the Tolerability of ALKS 4230 Plus Pembrolizumab in Ovarian CancerIra Winer, MD, PhD, discusses the tolerability of ALKS 4230 plus pembrolizumab in ovarian cancer.
Latest:
Dr. Ghobrial on Antibodies for Multiple Myeloma TreatmentIrene Ghobrial, MD, director, Michele & Stephen Kirsch Laboratory, senior physician, Dana-Farber Cancer Center Institute, discusses the use of monoclonal antibodies for the treatment of multiple myeloma.
Latest:
Disparities in Multiple Myeloma Care: The Path Toward Health EquityExpert panelists share their closing thoughts on the path to improve health equity in multiple myeloma management for racial and ethnic minority groups.
Latest:
Lung Cancer State of the Science Summit Recap | Chaired by: Isabel Preeshagul, DO, MBSIsabel Preeshagul, DO, MBS, and colleagues share updates from across the lung cancer space as discussed in a recent State of the Science Summit.
